Healthy Clinical Trial
Official title:
Effects of Plyometric- and Cycle-Based High-Intensity Interval Training on Body Composition, Aerobic Capacity, and Muscle Function in Young Females: a Field-based Group Fitness Assessment
Verified date | June 2023 |
Source | Kennesaw State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial was to compare to different types of high-intensity interval training in young, healthy females. The main questions were: Will changes in body composition differ between the two interventions? Will changes in endurance and muscle performance differ between the two interventions? Participants were randomized to 8 weeks of high-intensity interval training involving body weight, plyometric exercises or cycling only. Researchers compared changes in endurance performance, body composition, and muscle performance to determine if there were differences between groups.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 21, 2018 |
Est. primary completion date | November 21, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Between 18-35 years of age - Female - Currently participating in 2-4 days of structured exercise for 30-75 minutes for the last 6 months Exclusion Criteria: - Currently participating in these exercise formats (2x/week within last 3 months) - Engaging in high intensity interval training for more than 30 min/week - Have diagnosed disorders/diseases in the following: cardiovascular, pulmonary, immunological, or metabolic - Current musculoskeletal injuries - Pregnant or think you may be pregnant - Currently taking any non-steroidal anti-inflammatory drug(s) or steroidal drug(s) - Currently a smoker or has consistently smoked within the last year - Has a positive written or verbal pre-study drug screen including alcohol (more than 7 drinks/week), THC/cannabinoids, amphetamines, benzodiazepines, cocaine, opioids, phencyclidine, barbiturates, cotinine. - Currently taking any medication that will significantly affect your heart rate response to exercise - If you miss four or more classes, you will be excluded from the study |
Country | Name | City | State |
---|---|---|---|
United States | Kennesaw State University | Kennesaw | Georgia |
Lead Sponsor | Collaborator |
---|---|
Kennesaw State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Weekly exercising heart rate | A descriptor of the exercise physiological intensity for both protocols | during 8-week exercise intervention | |
Other | Weekly exercising perceived effort | Perceived intensity derived from the rating of perceived exertion scale | during 8-week exercise intervention | |
Other | Calorie consumption at baseline | Amount of calories consumed at beginning and end of protocol | Pre-intervention | |
Other | Calorie consumption after 8-week intervention | Amount of calories consumed at beginning and end of protocol | At week 9 | |
Other | Protein consumption at baseline | Amount of protein consumed at beginning and end of protocol | Pre-intervention | |
Other | Protein consumption after 8-week intervention | Amount of protein consumed at beginning and end of protocol | At week 9 | |
Other | Peak heart during maximal testing at baseline | The highest heart rate attained during maximal exercise testing | Pre-intervention | |
Other | Peak heart during maximal testing after 8-week intervention | The highest heart rate attained during maximal exercise testing | At week 9 | |
Primary | Muscle composition at baseline | echo-intensity value derived from ultrasound that indicates the amount of fat infiltration in muscle | Pre-intervention | |
Primary | Muscle composition after 8-week intervention | echo-intensity value derived from ultrasound that indicates the amount of fat infiltration in muscle | At week 9 | |
Secondary | Fat mass at baseline | Amount of fat tissue a person possesses | Pre-intervention | |
Secondary | Fat mass after 8-week intervention | Amount of fat tissue a person possesses | At week 9 | |
Secondary | Group average growth hormone response (concentration at microLiters/Liters) at baseline | The acute, exercise-induced response for growth hormone | Pre-intervention | |
Secondary | Group average growth hormone response (concentration at microLiters/Liters) after 8-week intervention | The acute, exercise-induced response for growth hormone | At week 9 | |
Secondary | Countermovement jump height at baseline | Height of jump | Pre-intervention | |
Secondary | Countermovement jump height after 8-week intervention | Height of jump | At week 9 | |
Secondary | Time to peak torque at baseline | How quickly muscle torque is generated | Pre-intervention | |
Secondary | Time to peak torque after 8-week intervention | How quickly muscle torque is generated | At week 9 | |
Secondary | Maximal oxygen consumption at baseline | Standard measure of maximal oxygen consumption or peak aerobic capacity during exercise | Pre-intervention | |
Secondary | Maximal oxygen consumption after 8-week intervention | Standard measure of maximal oxygen consumption or peak aerobic capacity during exercise | At week 9 | |
Secondary | Body fat percentage at baseline | Relative amount of body fat a person possesses | Pre-intervention | |
Secondary | Body fat percentage after 8-week intervention | Relative amount of body fat a person possesses | At week 9 | |
Secondary | Fat-free mass at baseline | Amount of non-fat tissue a person possesses | Pre-intervention | |
Secondary | Fat-free mass after 8-week intervention | Amount of non-fat tissue a person possesses | At week 9 | |
Secondary | Peak torque at baseline | Strength of a muscle | Pre-intervention | |
Secondary | Peak torque after 8-week intervention | Strength of a muscle | At week 9 | |
Secondary | Muscle cross-sectional area at baseline | The size of a muscle | Pre-intervention | |
Secondary | Muscle cross-sectional area after 8-week intervention | The size of a muscle | At week 9 | |
Secondary | Muscle power at baseline | Product of torque and velocity as determined on a dynamometer | Pre-intervention | |
Secondary | Muscle power after 8-week intervention | Product of torque and velocity as determined on a dynamometer | At week 9 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |